INTERCEPT‐AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative Interviews Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners
Kelly Johnston, Carrie Presnall, Elizabeth Merikle, Stephanie Cline, Todd Feaster, Eric Siemers · 2025
Read INTERCEPT‐AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative Interviews Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners by Kelly Johnston, Carrie Presnall, Elizabeth Merikle, Stephanie Cline, Todd Feaster, Eric Siemers (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712847.txt.
Description
Kelly Johnston and co-authors published a research paper in 2025 on what people with early Alzheimer's disease hope a new drug would do for them. The team spoke with people who had just finished a phase 1 trial of an antibody drug, along with the partners who joined the trial at their side.
Twenty-eight pairs took part in long talks after the trial ended. Almost all named memory and thinking trouble as their worst burden, and many spoke of getting lost or low mood. Nearly nine in ten said the best a drug could do was keep the disease from getting worse. Holding on to daily skills, and still knowing loved ones, ranked high too. Drug makers can use such hopes to shape what trials measure.
Catalog record
| CREATOR | Kelly Johnston, Carrie Presnall, Elizabeth Merikle, Stephanie Cline, Todd Feaster, Eric Siemers |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |